Lactic Acid Bacteria Surface Display for HPV E7 Mucosal Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic vaccines for HPV-associated cancers, such as cervical intraepithelial neoplasia, only partially regress severe dysplasia to moderate dysplasia and fail to achieve normalcy, necessitating a more effective mucosal immunity-inducing therapeutic oral pharmaceutical composition for HPV infectious diseases and associated tumors.
Innovation Solution
A lactic acid bacterium-containing composition with a wild-type HPV E7 protein or its mutant, fused with an anchor protein, is used to induce mucosal immunity, where the E7 protein is expressed or bound to the bacterium's surface, providing a therapeutic oral pharmaceutical composition for treating HPV infections and associated tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic vaccines are used to treat HPV-associated cancers, then severe dysplasia can be regressed to moderate dysplasia, but normalcy cannot be achieved
Solution Approach 1:
The invention changes the delivery route parameter from parenteral to oral administration, and modifies the antigen presentation mechanism by expressing E7 proteins on the surface of lactic acid bacteria. This parameter change enables complete regression of severe dysplasia to normalcy by inducing stronger and more comprehensive mucosal immunity compared to existing vaccines.
Solution Approach 2:
Lactic acid bacteria serve as an intermediary carrier that presents HPV E7 proteins to the immune system through oral administration. The bacteria act as a natural adjuvant and delivery vehicle, enabling effective antigen presentation and immune induction without requiring injection, thereby achieving complete therapeutic regression.
2Reliability
If prophylactic HPV vaccines are administered, then HPV infection can be prevented, but they can only prevent two types of high-risk HPVs
Solution Approach 1:
The therapeutic vaccine composition is designed to target multiple high-risk HPV types by incorporating E7 proteins from different HPV strains. The oral lactic acid bacterium-based platform provides universal applicability across multiple HPV types, overcoming the limitation of existing vaccines that only cover two types.
3Reliability
If E7 proteins are continuously increased in expression in epithelial cells, then cervical cancer develops, but existing vaccines cannot eliminate cancer cells
Solution Approach 1:
The invention converts the harmful persistent E7 protein expression into a beneficial therapeutic target. By using E7 proteins as antigens presented on lactic acid bacteria, the body's immune system is activated to specifically recognize and eliminate cells with persistent E7 expression, turning the cancer-causing mechanism into the basis for cancer cell destruction.
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2A
AI summary
A lactic acid bacterium-containing composition including a lactic acid bacterium having a human papillomavirus (HPV) E7 protein-derived polypeptide on a surface thereof, wherein the HPV E7 protein-derived polypeptide is included in an amount of 0.03 µg to 1.0 µg per 1 × 108 lactic acid bacteria; a therapeutic oral pharmaceutical composition for at least one of an HPV infectious disease and an HPV-associated tumor which includes the lactic acid bacterium-containing composition; and a mucosal immunity-inducing agent which includes the lactic acid bacterium-containing composition.